Mild Behavioral Impairment is Associated With Incident Cognitive Decline Among Dementia-Free, Racially Diverse Older

Barbara L Fischer1, Carol A Van Hulle1, Derek L Norton1

  • 1Department of Neurology (BLF), University of Wisconsin-Madison, Madison, WI; Geriatric Research Education and Clinical Center (GRECC) Wm. S. Middleton VA Hospital (BLF, SB, CEG), Madison, WI; Wisconsin Alzheimer's Institute (CAVH, NHL, CEG), University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI; Wisconsin Alzheimer's Disease Research Center (CAVH, DLN, SB, DCG, CEG), University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI; Division of Geriatrics and Gerontology (CAVH, DLN, MFW, GE, SB, DCG, CEG), Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI; Department of Biostatistics and Medical Informatics (DLN), University of Wisconsin-Madison, Madison, WI; and the Department of Psychology (DCG), University of Wisconsin-Madison, Madison, WI.

Abstract

Insights

Mild behavioral impairment (MBI) is linked to faster cognitive decline and increased dementia risk in older adults. Early identification of these neuropsychiatric symptoms is crucial for better neurodegenerative disease management.

Area of Science:

  • Neuroscience
  • Gerontology
  • Psychiatry

Background:

  • Neuropsychiatric symptoms, including mild behavioral impairment (MBI), are common in aging.
  • Understanding the association between MBI and cognitive trajectory is vital for early intervention in neurodegenerative diseases.

Purpose of the Study:

  • To investigate the relationship between MBI and cognitive performance over time.
  • To determine if MBI predicts incident cognitive decline in a diverse older adult cohort.

Main Methods:

  • An observational cohort study followed 584 participants from the Wisconsin Alzheimer's Disease Research Center.
  • Neuropsychiatric Inventory (MBI) and cognitive tests (Trailmaking Tests A and B, Wechsler Logical Memory) were administered.
  • Linear mixed-effects models and Cox proportional hazard models analyzed cognitive changes and decline risk.

Main Results:

  • Participants with MBI showed significantly worse age-associated decline in Trailmaking Test B performance.
  • Baseline MBI was associated with a 2.84-fold increased risk of global cognitive decline (CDR >0).

Conclusions:

  • MBI is associated with accelerated cognitive decline and increased risk of dementia in older, diverse populations.
  • Recognizing late-life neuropsychiatric symptoms aids in the identification, prognostication, and treatment of neurodegenerative conditions.

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
515
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
770
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811